Lenacapavir (LEN) is an antiviral medication used to treat and prevent HIV/AIDS and was first approved for individuals with ...
Gilead study finds HIV can evolve to resist lenacapavir, but doing so hampers the virus' replication
Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including lenacapavir—HIV’s ability to evolve resistance to the breakthrough antiviral.
Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game ...
The common cold is typically caused by viruses, most often rhinoviruses, which infect the upper respiratory tract (nose and throat). 1 Zinc has been reported to block the replication of rhinovirus. By ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results